As of Aug 22
| +1.12 / +1.32%|
The 19 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 90.00, with a high estimate of 126.00 and a low estimate of 50.00. The median estimate represents a +4.90% increase from the last price of 85.80.
The current consensus among 20 polled investment analysts is to Hold stock in Alnylam Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.